Xia Dian, Liu Qi, Yan Songbai, Bi Liangkuan
Department of Urology, The Second Hospital of Anhui Medical University, Hefei, China.
Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Front Oncol. 2022 Jun 2;12:895315. doi: 10.3389/fonc.2022.895315. eCollection 2022.
As one of the common malignancies in the urinary system, kidney cancer has been receiving explorations with respect to its pathogenesis, treatment and prognosis due to its high morbidity, high mortality and low drug efficiency. Such epigenetic modifications for RNA molecules as N6-methyladenosine (m6A) usher in another perspective for the research on tumor mechanisms, and an increasing number of biological processes and prognostic markers have been revealed. In this study, the transcriptome data, clinical data and mutation spectrum data of KIRC in the TCGA database were adopted to construct an m6A-related lncRNA prognostic model. Besides, the predictive ability of this model for clinical prognosis was evaluated, and some compounds sensitive to therapies for KIRC were screened. The findings of this study demonstrate that this effective and stable model has certain clinical application value.
作为泌尿系统常见的恶性肿瘤之一,肾癌因其高发病率、高死亡率和低药物疗效,在发病机制、治疗和预后方面一直受到探索。诸如N6-甲基腺苷(m6A)等RNA分子的表观遗传修饰为肿瘤机制研究带来了新视角,并且已经揭示了越来越多的生物学过程和预后标志物。在本研究中,采用TCGA数据库中KIRC的转录组数据、临床数据和突变谱数据构建了一个与m6A相关的lncRNA预后模型。此外,评估了该模型对临床预后的预测能力,并筛选了一些对KIRC治疗敏感的化合物。本研究结果表明,这个有效且稳定的模型具有一定的临床应用价值。